Skip to content

Genentech’s Ocrevus shows positive action in multiple sclerosis study

September 11, 2020

Roche (OTCQX:RHHBY) unit Genentech announces new data from Phase IIIb CASTING study that shows Ocrevus (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who experienced a suboptimal response to their prior disease modifying therapy (DMT). Findings will be presented at the MSVirtual2020 meeting.

Approx. 75% of RRMS patients (492/658) had no evidence of disease activity (NEDA; brain lesions, relapses and worsening of disability) two years after switching to twice-yearly Ocrevus treatment in the primary analysis of the CASTING study.

Further, 78% of patients treated with only one prior DMT compared with 70% treated with two prior DMTs achieved NEDA.

A 97% treatment persistence for Ocrevus patients at 18 months, and strong adherence to infusions every six months, was seen in an interim analysis of more than 1,600 patients in the ongoing German CONFIDENCE study.

The CD20-directed cytolytic antibody, dosed every six months, is the only therapy approved for both relapsing (including relapsing-remitting MS) and active, or relapsing, secondary progressive MS (and clinically isolated syndrome in the U.S.) and primary progressive MS.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: